Mather Group LLC. Purchases New Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Mather Group LLC. purchased a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 1st quarter, according to its most recent disclosure with the SEC. The fund purchased 589 shares of the medical equipment provider’s stock, valued at approximately $72,000.

A number of other institutional investors have also recently added to or reduced their stakes in ZBH. OLD Point Trust & Financial Services N A bought a new stake in Zimmer Biomet during the 4th quarter worth approximately $26,000. Ables Iannone Moore & Associates Inc. bought a new stake in Zimmer Biomet during the 4th quarter worth approximately $30,000. Naples Money Management LLC bought a new stake in Zimmer Biomet during the 4th quarter worth approximately $35,000. Activest Wealth Management grew its holdings in Zimmer Biomet by 410.4% during the 4th quarter. Activest Wealth Management now owns 342 shares of the medical equipment provider’s stock worth $42,000 after acquiring an additional 275 shares during the last quarter. Finally, Blue Trust Inc. grew its holdings in Zimmer Biomet by 48.4% during the 4th quarter. Blue Trust Inc. now owns 469 shares of the medical equipment provider’s stock worth $52,000 after acquiring an additional 153 shares during the last quarter. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Stock Performance

Shares of ZBH stock opened at $107.86 on Friday. The firm has a 50-day moving average of $116.59 and a 200-day moving average of $121.51. The company has a market cap of $22.19 billion, a P/E ratio of 23.35, a P/E/G ratio of 1.91 and a beta of 1.02. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.66 and a quick ratio of 0.80. Zimmer Biomet Holdings, Inc. has a one year low of $102.00 and a one year high of $147.50.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.94 EPS for the quarter, beating the consensus estimate of $1.87 by $0.07. The company had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. Zimmer Biomet had a net margin of 12.93% and a return on equity of 12.70%. The firm’s revenue for the quarter was up 3.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.89 earnings per share. Equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.1 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 31st. Investors of record on Wednesday, June 26th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Wednesday, June 26th. This represents a $0.96 annualized dividend and a yield of 0.89%. Zimmer Biomet’s payout ratio is currently 20.78%.

Analysts Set New Price Targets

ZBH has been the topic of a number of analyst reports. Argus raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating and set a $150.00 price objective on the stock in a research note on Tuesday, May 21st. Oppenheimer upped their price objective on shares of Zimmer Biomet from $150.00 to $155.00 and gave the company an “outperform” rating in a research note on Friday, May 3rd. Evercore ISI upped their price objective on shares of Zimmer Biomet from $125.00 to $130.00 and gave the company an “in-line” rating in a research note on Thursday, April 4th. The Goldman Sachs Group initiated coverage on shares of Zimmer Biomet in a research note on Thursday, May 30th. They issued a “neutral” rating and a $129.00 price objective on the stock. Finally, Barclays dropped their target price on shares of Zimmer Biomet from $130.00 to $125.00 and set an “underweight” rating on the stock in a research report on Friday, May 31st. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $133.75.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.